592 related articles for article (PubMed ID: 20720050)
21. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.
Hänscheid H; Sweeney RA; Flentje M; Buck AK; Löhr M; Samnick S; Kreissl M; Verburg FA
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1284-8. PubMed ID: 22526964
[TBL] [Abstract][Full Text] [Related]
22. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
23. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors.
Haug AR; Rominger A; Mustafa M; Auernhammer C; Göke B; Schmidt GP; Wängler B; Cumming P; Bartenstein P; Hacker M
J Nucl Med; 2011 Nov; 52(11):1679-83. PubMed ID: 21976529
[TBL] [Abstract][Full Text] [Related]
24. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
25. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.
Kratochwil C; Stefanova M; Mavriopoulou E; Holland-Letz T; Dimitrakopoulou-Strauss A; Afshar-Oromieh A; Mier W; Haberkorn U; Giesel FL
Mol Imaging Biol; 2015 Jun; 17(3):313-8. PubMed ID: 25319765
[TBL] [Abstract][Full Text] [Related]
26. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
27. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography.
Koch W; Auernhammer CJ; Geisler J; Spitzweg C; Cyran CC; Ilhan H; Bartenstein P; Haug AR
Mol Imaging; 2014; 13():1-10. PubMed ID: 24824963
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
29. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
30. [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].
Haug AR; Assmann G; Rist C; Tiling R; Schmidt GP; Bartenstein P; Hacker M
Radiologe; 2010 Apr; 50(4):349-54. PubMed ID: 20333502
[TBL] [Abstract][Full Text] [Related]
31. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.
Zwirtz K; Hardt J; Acker G; Baur ADJ; Pavel M; Huang K; Brenner W; Prasad V
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745849
[No Abstract] [Full Text] [Related]
33. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R
Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927
[TBL] [Abstract][Full Text] [Related]
34. Inflammation-Based Index and
Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
36. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
Kaewput C; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
38. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
Wong KK; Frey KA; Niedbala J; Kaza RK; Worden FP; Fitzpatrick KJ; Dewaraja YK
Nucl Med Commun; 2022 Aug; 43(8):892-900. PubMed ID: 35703269
[TBL] [Abstract][Full Text] [Related]
39. The predictive value of pretherapy [
Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
[TBL] [Abstract][Full Text] [Related]
40. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]